Table 3.
The risk of impaired glucose regulation and type 2 diabetes associated with a 10 ng/ml increase in serum lipocalin-2
| Model | IGR (n = 984) | p valuea | impaired glucose regulation and type 2 diabetes (n = 1376) | p valueb |
|---|---|---|---|---|
| Model 1 | 1.48 (1.34-1.87) | < 0.001 | 1.55 (1.43-1.97) | < 0.001 |
| Model 2 | 1.43 (1.31-1.75) | < 0.001 | 1.47 (1.38-1.85) | < 0.001 |
| Model 3 | 1.40 (1.31-1.81) | < 0.001 | 1.41 (1.29-1.81) | < 0.001 |
| Model 4 | 1.35 1.24-1.65) | < 0.001 | 1.38 (1.25-1.81) | < 0.001 |
| Model 5 | 1.30 (1.23-1.62) | 0.009 | 1.31 (1.21-1.69) | < 0.001 |
Values are ORs (95% CI)
Model 1: Unadjusted. Model 2: Adjusted for age, sex, smoking (yes/no), alcohol drinking (yes/no), family history of diabetes (yes/no). Model 3: Further adjusted for HOMA-IR, BMI, waist/hip ratio and adiponectin. Model 4: Further adjusted for serum triacylglycerol, total cholesterol, HDL- and LDL-cholesterol. Model 5: Further adjusted for inflammatory factors (CRP and CXCL5). aFor the risk of IGR, we defined subjects with normal glucose regulation as 0 (n = 1143) and IGR as 1 (n = 984), excluding type 2 diabetes (n = 392) from the analysis. bFor the risk of combined IGR and type 2 diabetes, we defined subjects with normal glucose regulation as 0 (n = 1143) and combined IGR and type 2 diabetes as 1 (n = 1376).